Background: Basophil activation contributes to inflammatory reactions, especially in allergy. It is controlled, both positively and negatively, by several mechanisms. High-affinity IgE receptors (FcεRI) generate a mixture of activation and inhibition signals when aggregated, the ratio of which depends on the concentration of allergen recognized by receptor-bound IgE. Low-affinity IgG receptors (FcgRIIA/B) generate inhibition signals when coengaged with FcεRI by allergen-antibody immune complexes. Commensal and probiotic bacteria, such as Lactobacillus paracasei, generate inhibition signals through still unclear mechanisms.
Basophils have been recognized to play critical roles in an increasing number of pathologic conditions. Particularly well known is their contribution to allergy as initiators of IgE-induced acute reactions. Basophils also account for late-phase 1 and chronic 2 allergic inflammation. They are a major source of IL-4 that promotes chemokine and cytokine secretion by type 2 innate lymphoid cells, leading to eosinophilic inflammation. 3, 4 Autoreactive IgE anti-double-stranded DNA antibodies associated with basophil activation were found in patients with systemic lupus erythematosus 5 and were correlated with the severity of nephritis. 6 Under normal conditions, however, basophils are under the control of a variety of regulatory mechanisms that might prevent the pathogenic consequences of their activation.
High-affinity IgE receptors (FcεRI) activate basophils when aggregated by a plurivalent allergen that binds to FcεRI-bound IgE antibodies. However, FcεRI aggregation generates not only activation signals but also inhibition signals, the ratio of which depends on the degree of receptor aggregation (ie, on antigen concentration). Positive signals are dominant over negative signals up to an optimal concentration, beyond which negative signals become dominant and abrogate basophil activation. This autoinhibition of FcεRI signaling depends on the SH2 domain-containing inositol 5 phosphatase 1 (SHIP1). 7 By hydrolyzing phosphatidylinositol 3,4,5-trisphosphate, which mediates the membrane recruitment of cytosolic signaling molecules with a pleckstrin homology domain, 8 SHIP1 inhibits distal signaling events, among which are Ca 21 mobilization, activation of extracellular signal-regulated kinase 1/2, c-Jun N-terminal and p38 mitogen-activated protein kinases, and their biological consequences.
FcgRIIB-dependent negative regulation further controls mast cell 9 and basophil 10 activation. Because 1,000,000-fold more IgG than IgE (in milligrams per milliliter vs nanograms per milliliter) circulate in the bloodstream, allergens are likely to interact with FcεRI-bound IgE as IgG immune complexes rather than in isolation. Therefore allergens do not simply aggregate FcεRI; they also coaggregate FcεRI with low-affinity IgG receptors expressed on the same cell. These include activating (FcgRIIA) and inhibitory (FcgRIIB) receptors. Because human basophils express small amounts of FcgRIIA (10-fold less than blood monocytes) but high amounts of FcgRIIB (3-fold more than blood B cells), negative regulation is dominant when FcgRIIA and FcgRIIB are coengaged by immune complexes on basophils from healthy donors. 10 Inhibition induced under these conditions also depends on SHIP1, high amounts of which are recruited by FcgRIIB. FcgRIIB indeed contains an immunoreceptor tyrosine-based inhibition motif, which, when phosphorylated, has high affinity for the SH2 domain of SHIP1. 11 Increasingly, commensal bacteria have been understood to play critical roles in the homeostasis that controls inflammatory processes, and IgE-dependent human basophil activation can be profoundly but reversibly inhibited when PBMCs are exposed to specific strains of Lactobacillus paracasei before challenge. 12 Inhibition requires direct contact between cells and bacteria, but the molecular mechanism accounting for inhibition was not elucidated.
These regulatory mechanisms have been regarded increasingly as potential therapeutic tools for controlling the effector phase of inflammation, especially in allergic patients. Allergen immunotherapy is currently thought to depend on the generation of regulatory T cells that promote a state of ''tolerance'' to allergen by dampening T H 2 responses. 13 Nevertheless, it induces high amounts of allergen-specific IgG antibodies that have long been believed to compete with specific IgE for antigen.
14 IgG antibodies found in the sera of patients treated by immunotherapy were shown recently to dampen basophil activation through a FcgRIIB-dependent mechanism. 15, 16 Consumption of probiotic bacteria has been proposed as a prophylactic measure to prevent either onset of allergies in healthy subjects or the outcome of allergic symptoms in allergic patients. 17 Bispecific molecules capable of coligating FcgRIIB with either FcεRI 18 or FcεRI-bound IgE 19, 20 have been generated as potential new treatments of allergies, and genetically engineered IgG antibodies have been produced, among which are anti-IgE antibodies, the affinity of which for FcgRIIB is several hundred-fold higher than that for native antibodies. 21, 22 The efficacy of these therapeutic approaches implies that the regulatory mechanisms on which they lie are functional in allergic patients. These mechanisms were indeed described and studied in basophils from healthy donors but they were not examined in allergic patients. If, for whatever reason, 1 or several of these mechanisms are deficient in patients with 1 or several allergic conditions, therapeutic tools can be disqualified for 1 or several allergic diseases. On the other hand, finding that negative regulation is impaired in some or all allergic patients, irrespective of the mechanism, can provide a clue to understanding the cause of the allergies. What makes patients allergic and/or what prevents nonallergic subjects from being allergic is not known, and one possibility is that negative regulation is operational and protective in nonallergic subjects but impaired in allergic patients.
Therefore we examined FcεRI-dependent positive and negative regulation, FcgRIIB-dependent negative regulation, and L paracasei-induced inhibition in basophils from patients who are routinely taken care of in an allergology outpatient clinic. We found that all regulatory mechanisms examined were fully functional in patients, irrespective of their pathologic conditions.
METHODS

Patients and healthy donors
A total of 77 patients (57 female and 20 male patients; 18-77 years old [mean, 44 years]) were enrolled in the study over a 3-month period (from October 22, 2013, to January 29, 2014). Inclusion criteria were as follows: age greater than 18 years, presence of an allergic disease, prescription of a blood test, and agreement to be enrolled in the study by giving their informed consent. Exclusion criteria were as follows: inability to provide consent, presence of evolutive neoplasia or infectious or inflammatory disease, receipt of glucocorticoid or antihistamine medication less than 1 week earlier, and receipt of immunosuppressive treatment, irrespective of the reason. Patients were recruited as part of the Institut Pasteur 2013-13 clinical study with ethical approval from the Comit e de Protection des Personnes Ile-de-France II.
Diagnostics were based on clinical symptoms, skin test results, and biological measurements. Patients were classified by clinicians into 5 groups as a function of diagnosis (Fig 1, A In practice, one 5-to 10-mL blood sample was collected in EDTA during a blood test that had been prescribed to investigate the clinical condition of the patient independent of the study. One blood sample only from each patient was examined. Blood from 1 to 5 patients was tested every day together with 1 blood sample drawn on the same day from a healthy donor, which was included as a positive control in every experiment. All blood samples were examined with the same protocol under the same conditions. Data from all blood samples were included in the analysis except (1) 1 Group A and 3 Group C samples that contained insufficient basophils for being analyzed and (2) 
Experimental procedures
Cells. PBMCs isolated from peripheral blood by means of centrifugation through Ficoll-Hypaque were resuspended at 1 3 10 6 cells/mL in culture medium (RPMI 1640 supplemented with 10% FCS, 2 mmol/L L-glutamine, 1% sodium pyruvate, 1% nonessential amino acids, and 1% HEPES buffer) and sensitized by an overnight incubation at 378C with 3 mg/mL myeloma rat IgE (rIgE) IR162 (IMEX, Universit e de Louvain, Brussels, Belgium). PBMCs were placed at 378C for overnight incubation within 1 hour after blood was drawn. They were then submitted to the 10 experimental conditions shown in Table I . All 10 conditions were applied to PBMCs from the same donor in the same experiment.
Bacteria. L paracasei was the same strain (CNCM I-1518) used in our previous work. 12 It was cultured in Mann-Rogosa-Sharpe broth at 378C for 48 hours, washed, resuspended in PBS, and adjusted to an OD 600 value of 2. Ten microliters of L paracasei was added to 90 mL of PBMCs together with rIgE. Therefore cells were incubated overnight with bacteria.
Challenge. Cells were washed extensively and stimulated for 20 minutes at 378C with equimolar concentrations of the following 4 reagents: (1) 15 mg/mL rabbit anti-human IgE antibody (RAHE IgG; Dako Cytomation, Trappes, France); (2) 10 mg/mL F(ab9) 2 fragments obtained by means of peptic digestion of the same antibodies (RAHE F[ab9] 2 ); (3) 15 mg/mL mouse anti-rat immunoglobulin antibody (MAR IgG; Jackson ImmunoResearch, West Grove, Pa); and (4) 10 mg/mL F(ab9) 2 fragments of the same antibodies (MAR F[ab9] 2 ; Jackson ImmunoResearch). Basophils were identified as FcεRI 1 CD203c 1 cells, as previously described, 28 and basophil activation was monitored by using CD203c upregulation, as previously described. 10 Immunofluorescence analysis. 
Statistical analysis
Statistical analyses were performed with SAS 9.3 (SAS Institute, Cary, NC) and R 3.3.0 software. Either raw values or variations between 2 conditions were analyzed. Wilcoxon signed-rank tests were used to compare 2 conditions in healthy donors. Kruskal-Wallis tests were used to compare data between independent groups, and Friedman tests were used to compare data between paired groups. In addition, a Bonferroni-Holm adjustment was performed for post hoc comparisons. Results with P values of less than .05 were considered significant.
RESULTS
FcεRI and FcgRIIA/B expression, anti-IgE-induced activation, FcεRI autoinhibition, and FcgRIIB-dependent inhibition were compared in basophils from healthy blood donors (Group N) and basophils from patients with respiratory allergy (Group A), anaphylaxis antecedents (Group B), chronic urticaria (Group C), atopic dermatitis (Group D), or respiratory allergy plus 1 other allergic condition (Group A 1 ). The effects of L paracasei were examined on FcεRI and FcgRIIA/B expression, anti-IgE-induced activation, FcεRI autoinhibition, and FcgRIIB-dependent inhibition in basophils from the same 6 groups of donors.
Basal parameters
As expected 29 and as observed previously, 28 plasma IgE levels were significantly greater in patients with atopic dermatitis (Group D) than in other allergic patients (Fig 1, B) . Consequently, basophils from Group D patients displayed more FcεRI-bound hIgE and expressed more FcεRI than basophils from healthy donors (Fig 2, A) . No statistically significant differences in basophil numbers were observed among the 5 groups of patients ( Fig 1, C) . No statistically significant difference in CD203c expression was observed between basophils from the 5 groups of patients and those from healthy donors (Fig 2, A) . Basophils from all 5 groups of patients expressed comparable amounts of FcgRII as basophils from healthy donors when assessed with either FcgRIIA-specific or FcgRIIA1B-specific mAbs (Fig 3, A) . Because FcgRIIA expression is very low and FcgRIIB expression is very high in human basophils, 10 FcgRIIA1B-specific mAbs reveal essentially FcgRIIB.
Effect of L paracasei on resting cells
An overnight incubation of PBMCs with L paracasei altered several parameters on resting basophils from healthy donors. CD203c expression was increased almost 2-fold, whereas FcεRI-bound hIgE levels were decreased. Neither FcεRI expression (in spite of a statistically significant difference; Fig 2, B) nor FcgRIIA expression were altered detectably (Fig 3, B) , whereas FcgRIIA1B expression was decreased by one third (Fig 3, B) .
L paracasei similarly affected basophils from healthy donors and basophils from allergic patients. However, L paracasei-induced differences that were statistically different in basophils from healthy donors were not statistically different in basophils from allergic patients (Fig 2, B, and 3, B) . Also, both increased FcεRI expression and increased FcεRI-bound IgE levels seen in basophils from patients with atopic dermatitis decreased to levels that were not statistically different from levels seen in basophils from healthy donors and other patients after exposure to L paracasei (Fig 2, B) .
FcεRI-dependent basophil activation
When recognizing membrane-bound endogenous hIgE, RAHE F(ab9) 2 fragments aggregate FcεRI and trigger basophil activation that can be monitored by assessing upregulation of CD203c with flow cytometry (Table I , condition 1). Indeed, RAHE F(ab9) 2 increased CD203c expression 3-fold in basophils from healthy donors. A similar 2-to 3-fold upregulation of CD203c expression was induced under the same conditions in basophils from the 5 groups of patients (Fig 4, A) . However, one should remember that basophils from 10 patients of Group C which could be analyzed did not respond to RAHE F(ab9) 2 . Basophils from the remaining samples responded similarly to basophils from healthy donors, and the slight differences in CD203c upregulation seen in basophils from the various groups of patients were not statistically significant. All FcεRI are not occupied by endogenous hIgE. Therefore cells were sensitized passively with rIgE. Human FcεRI can bind rIgE with a similarly high affinity as hIgE. 30 When recognizing receptor-bound rIgE, MAR F(ab9) 2 fragments aggregate FcεRI and trigger basophil activation (Table I, condition 5). MAR antibodies do not cross-react with hIgE. 10 MAR F(ab9) 2 increased CD203c expression 2-to 3-fold in basophils from healthy donors, as well as in basophils from the 5 groups of patients (Fig 4, B) . Basophils from the Group C patients that were not activated by RAHE F(ab9) 2 were not activated by MAR F(ab9) 2 either. Differences in CD203c upregulation seen in basophils from the various groups of patients were not statistically significant.
FcgRIIB-dependent inhibition of FcεRI-dependent basophil activation
When recognizing receptor-bound hIgE, intact RAHE IgG antibodies coaggregate FcεRI through their Fab portions and FcgRIIA1B through their Fc portion on the same cell (Table I, condition 2). Under this condition, FcgRIIB inhibit FcεRI-dependent activation. 10 Inhibition can be monitored by comparing CD203c upregulation induced under condition 2 with CD203c upregulation induced under condition 1. RAHE IgG induced a 40% to 60% inhibition in healthy donors. Inhibitions of comparable magnitudes were observed in basophils from the 5 groups of patients (Fig 5, A) . Differences between healthy donors and patients of the 5 groups were not statistically significant.
When recognizing receptor-bound rIgE, intact MAR IgG antibodies coaggregate FcεRI through their Fab portions and FcgRIIB1A through their Fc portion on the same cell (Table I,  condition 7) , and FcgRIIB inhibit FcεRI-dependent activation. Inhibition was monitored by comparing CD203c upregulation induced under condition 7 with CD203c upregulation induced under condition 5. MAR IgG induced a 670% inhibition in basophils from healthy donors and inhibitions of comparable magnitudes in basophils from the 5 groups of patients (Fig 6, A) .
L paracasei-induced inhibition of FcεRI-dependent basophil activation
Overnight incubation of PBMCs with L paracasei strain CNCM I-1518 inhibits the subsequent IgE-mediated FcεRI-dependent activation of human basophils. 12 The inhibitory effect of L paracasei was examined on basophil activation induced by RAHE F(ab9) 2 (Table I , condition 2) or MAR F(ab9) 2 (Table I , condition 6). Inhibition was assessed by comparing conditions 2 and 1 and conditions 5 and 6. L paracasei induced a more than 80% inhibition of basophil activation, irrespective of whether induced by RAHE F(ab9) 2 (Fig 5, B) or MAR F(ab9) 2 (Fig 6, B) . L paracasei induced inhibitions of comparable magnitudes in basophils from healthy donors and from the 5 groups of patients, irrespective of whether challenged with RAHE F(ab9) 2 or with MAR F(ab9) 2 .
MAR F(ab9) 2 -induced FcεRI autoinhibition
As expected, CD203c upregulation displayed a bell-shaped curve when basophils passively sensitized with rIgE were challenged with increasing concentrations of MAR F(ab9) 2 (data not shown). Indeed, an excess of ligand induces dose-dependent inhibition of cell activation that depends on the lipid phosphatase SHIP1. 7 This FcεRI autoinhibition was assessed by comparing CD203c upregulation induced by an optimal concentration of 10 mg/mL (1X) MAR F(ab9) 2 (Table I , condition 1) and CD203c upregulation induced by 2 supraoptimal concentrations (93 and 183) of MAR F(ab9) 2 (Table I, condition  9 ). 93 MAR F(ab9) 2 induced a 650% inhibition in basophils from healthy donors (Fig 6, D) , and 183 MAR F(ab9) 2 induced an inhibition of 660% (Fig 6, E) . FcεRI autoinhibition was of comparable magnitudes in basophils from healthy donors and basophils from patients. One notices that the nonstatistically significant differences between the 5 groups of patients observed with 93 MAR F(ab9) 2 were blunted with 183 MAR F(ab9) 2 .
FcgRIIB-dependent inhibition or FcεRI autoinhibition plus L paracasei-induced inhibition
Unlike the well-established SHIP1-mediated mechanism of FcεRI autoinhibition and FcgRIIB-dependent inhibition, the molecular mechanism by which L paracasei inhibits basophil activation is poorly known. We wondered whether L paracasei-induced inhibition would compete with SHIP1-mediated inhibition. PBMCs that had been exposed to L paracasei were challenged with RAHE IgG (Table I , condition 4), MAR IgG (Table I , condition 8), or supraoptimal concentrations of MAR F(ab9) 2 (Table I , condition 10). Inhibition of CD203c upregulation observed under these conditions was compared with inhibition induced by the same ligands in cells not exposed to L paracasei (Table I, conditions 3, 7, and 9, respectively) and with inhibition induced by L paracasei alone (Table I , conditions 2 and 6).
L paracasei plus RAHE IgG-induced inhibition of normal basophil activation (Fig 5, C) was much greater than inhibition induced by RAHE IgG alone (Fig 5, A) and slightly greater than inhibition induced by L paracasei alone (Fig 5, B) . L paracasei 1 RAHE IgG-induced inhibitions were similarly greater than inhibition induced by L paracasei or RAHE IgG alone in basophils from patients and in basophils from healthy donors, except in Groups B and D, where inhibition induced by L paracasei plus RAHE IgG (Fig. 5, C) was similar to inhibition induced by L paracasei alone (Fig 5, B) . However, differences between heathy donors and the 5 groups of patients were not statistically significant.
L paracasei plus MAR IgG-induced inhibition of normal basophil activation (Fig 6, C) was also much greater than inhibition induced by MAR IgG alone (Fig 6, A) or L paracasei alone (Fig 6, B) . L paracasei plus MAR IgG-induced inhibition was similarly greater than inhibition induced by L paracasei or MAR IgG alone in basophils from patients and basophils from healthy donors.
Inhibition of normal basophil activation induced by L paracasei and a supraoptimal concentration of MAR F(ab9) 2 (Fig 6, F and G) was greater than inhibition induced by an excess of MAR F(ab9) 2 alone (Fig 6, D and E) but of the same magnitude as inhibition induced by L paracasei alone (Fig 6, B) . A similar additive effect was observed in basophils from the 5 groups of patients.
DISCUSSION
Our investigation documents the functional state of blood basophils in a sample of 77 patients who consulted an allergology outpatient clinic over a period of 3 autumn-winter months. It was focused on mechanisms known to regulate, either positively or negatively, activation of basophils from healthy donors. The unexpected overall result is that, when compared with basophils from healthy donors, patients' basophils were neither hyperreactive to positive regulation nor hyporeactive to negative regulation, irrespective of their allergic manifestations. This result has important consequences for our understanding of the cause of allergies and for new therapeutic strategies being developed.
First, we noticed both expected and unexpected abnormalities in 2 groups of patients. As expected, basophils from patients with atopic dermatitis (Group D) expressed more FcεRI and displayed more FcεRI-bound hIgE than basophils from healthy donors or other patients. These differences were correlated with increased plasma IgE levels, which are associated classically with atopic dermatitis. 29 It is well known that FcεRI expression is upregulated by IgE, 31 which slows the intracellular degradation of receptors occupied by IgE. 32 Unexpected basophil abnormalities were observed in some but not all patients with chronic urticaria (Group C). Three among the 19 patients included in this group (1 of the 20 Group C samples could not be processed for irrelevant technical reasons) had basophil numbers too low for study, and the basophils of 10 others did not respond to FcεRI aggregation, either by RAHE or MAR F(ab9) 2 fragments. The remaining 6 Group C patients had similar numbers of basophils, which responded similarly as healthy donor basophils to FcεRI aggregation. Therefore Group C might contain 2 subgroups of patients, 68% (13/19) of whom have low basophil numbers or hyporeactive basophils, and 32% (6/19) of whom have normal numbers of normally reactive basophils. Chronic urticaria is a nosologically heterogeneous ensemble of diseases, some of which are autoimmune. Autoantibodies against the a subunit of FcεRI are found in the sera of 30% to 60% of patients with chronic urticaria, 33, 34 which are thought to trigger basophil and/or mast cell activation responsible for clinical manifestations. Whether such autoantibodies were present in the sera of patients with abnormal basophil counts or functions is not known. Both low basophil numbers or hyporeactive basophils could result from a chronic stimulation by anti-FcεRI autoantibodies. In addition, an unknown factor present in the serum of patients with active chronic idiopathic urticaria was found recently, which inhibits FcεRI-dependent histamine release by basophils. 35 Remarkably, FcεRI expression and functions were unaltered in basophils from all other patients. Basophils from all patients except those with atopic dermatitis expressed comparable amounts of FcεRI as basophils from healthy donors. Basophils from all patients except half of the patients with chronic urticaria but including patients with atopic dermatitis with increased FcεRI expression were activated similarly as basophils from healthy donors by an optimal concentration of F(ab9) 2 anti-IgE, irrespective of whether through endogenous hIgE or exogenous rIgE. Activation of basophils from all patients, including hyporesponsive basophils from half of the patients with chronic urticaria, was inhibited similarly by an excess of MAR F(ab9) 2 fragments as basophils from healthy donors. Therefore basophils from allergic patients did not overexpress FcεRI, were not overresponsive to FcεRI aggregation-triggered activation signals, and were not hyporesponsive to FcεRI hyperaggregation-triggered inhibition signals.
Likewise, FcgRIIA and FcgRIIB expression and function were unaltered in basophils from all patients. FcgRIIA expression was comparable on basophils from patients as on basophils from healthy donors. Whether the activating properties of this immunoreceptor tyrosine-based activation motif-containing receptor were as modest as previously observed in basophils from healthy donors 10 was not examined in basophils from A B FIG 4 . Basophil activation induced by aggregating FcεRI-bound hIgE or rIgE with corresponding F(ab9) 2 fragments. Cartoons in the upper part of the figure schematize the experimental settings. They illustrate how RAHE F(ab9) 2 (A) and MAR F(ab9) 2 (B) can similarly aggregate basophil FcεRI when binding to hIgE and rIgE, respectively. PBMCs from the 6 groups of subjects studied and passively sensitized with rIgE were challenged with RAHE F(ab9) 2 (Fig 4, A) or MAR F(ab9) 2 (Fig 4, B) . CD203c was monitored in basophils, and CD203c upregulation observed after challenge was plotted as the fold increase in the lower part of the figure. The dotted line (fold increase 5 1) corresponds to baseline levels (no challenge). MFI, Mean fluorescence intensity.
patients. FcgRIIA1B expression (ie, because of the markedly unbalanced expression of the 2 receptors, primarily FcgRIIB expression) was comparable on basophils from patients and those from healthy donors. Whether assessed with RAHE IgG or MAR IgG, FcgRIIB-dependent negative regulation of FcεRI-dependent activation was similar in basophils from patients of all 5 groups as in those from healthy donors. Therefore basophils from allergic patients did not express more FcgRIIA or less FcgRIIB, and their activation was not less efficiently inhibited by the coaggregation of FcεRI with FcgRIIA1B than that of normal basophils. L paracasei had a similar affect on basophils from all groups of patients and those from healthy donors. Basal CD203c expression was increased similarly, whereas FcεRI-bound hIgE and FcgRIIB expression was similarly decreased; FcεRI and FcgRIIA expression was similarly not changed. Noticeably, L paracasei decreased both augmented FcεRI expression and FcεRI-bound hIgE levels back to normal in basophils from patients with atopic dermatitis. L paracasei inhibited similarly FcεRI-dependent activation in basophils from all patients and healthy donors, irrespective of whether induced by RAHE F(ab9) 2 or by MAR F(ab9) 2 . L paracasei-induced inhibition was additive with FcεRI autoinhibition induced by an excess of ligand not only in basophils from healthy donors, which had not been examined before, but also in basophils from all 5 groups of patients. Likewise, L paracasei-induced inhibition was additive with FcgRIIB-dependent inhibition both in basophils from healthy donors and those from patients, despite the decreased FcgRIIB expression induced by L paracasei. Therefore L paracasei inhibited equally efficiently FcεRI-dependent activation in basophils from allergic patients and those from healthy donors, and this inhibition was additive with both FcεRI autoinhibition and FcgRIIB-dependent inhibition.
Our study was focused on basophils. Basophils are few among the various effector cells that contribute to allergic manifestations. They might not be representative of other cells, especially mast cells, which are dispersed throughout tissues in which they differentiate into several types, depending on the environment. Allergic diseases can generate a variety of symptoms depending on the cell types involved and the location at which the reaction occurs. However, allergic diseases can arise as a consequence of abnormalities that can affect specific regulatory mechanisms shared by several cell types. FcεRI-, FcgRIIB-, and microbiota-dependent signaling, which control the activation of both basophils and other myeloid cells, are such mechanisms. If so, basophils can be used as readily accessible sample cells that can provide information on defects that might contribute to allergies.
Our study was focused on basophil activation. We found no differences between basophils from healthy donors and those from allergic patients and, among the latter, between basophils from patients with different allergic diseases when assessing basophil activation by measuring CD203c upregulation in response to FcεRI engagement under several conditions. Our results do not imply that the secretory responses of basophils from patients of all 5 groups and healthy donors were identical. Monitoring CD203c expression provides quantitative but no qualitative information on basophil activation. Also, the 5 groups of patients were chosen arbitrarily, depending on symptomatology. Other criteria could have been chosen (eg, the allergens involved), which might not have led to the same results. Finally, because of the small number of patients included in each group, one cannot exclude that nonstatistically significant differences observed here might become significant when more patients are included.
Our study was focused on basophil activation in vitro. The aim or our work was to investigate whether the regulatory mechanisms known to operate in basophils from healthy donors were functional in basophils from allergic patients. Such a study has limitations inherent to any in vitro investigation, but it also has advantages. The experimental conditions used permitted a comparison between basophils from unknown healthy donors and basophils from patients with different allergic diseases and allergic responses to a variety of allergens, which would not have been possible otherwise. Indeed, these experimental conditions, which were far from physiologic conditions, enabled all basophils to be challenged under the same conditions with the same reagents and therefore compared rigorously. Because they were obtained in vitro, our results neither exclude nor support the possibility that environmental influences to which basophils are exposed when circulating in the blood of patients might alter in vivo the regulatory mechanisms that we found to function normally in vitro. Such extrinsic factors were not investigated. Cartoons in the upper part of the figure schematize the experimental settings used. They illustrate how RAHE F(ab9) 2 can aggregate basophil FcεRI when binding to hIgE, whereas intact RAHE IgG can coaggregate FcgRII and FcεRI on the same cells. PBMCs from the 6 groups of subjects studied were incubated with (B and C) or without (A) L paracasei. They were challenged with RAHE F(ab9) 2 (Fig 5, B) or RAHE IgG (Fig 5, A and  C) . CD203c was monitored in basophils, and CD203c upregulation induced by RAHE F(ab9) 2 in cells not exposed to L paracasei (data not shown) was used as a 100% response to calculate the percentage inhibition induced by RAHE IgG (Fig 5, A) , L paracasei (Fig 5, B) , and RAHE IgG plus L paracasei (Fig 5, C) .
Thus our results exclude neither that too much specific IgE antibodies nor that not enough specific IgG antibodies were produced in response to allergens in some or all allergic patients.
Our study might contribute to sorting out causative factors in allergy. Indeed, we found that no obvious intrinsic abnormality dampens regulatory mechanisms that control basophil activation in allergic patients. This was far from being expected. This finding does not exclude that these mechanisms might not be efficiently used or even not used at all in allergic patients. However, it excludes that intrinsic defects in basophils, irrespective of whether resulting in hyperresponsiveness to IgE-induced activation or hyporesponsiveness to inhibitory mechanisms, explain the allergic phenotype of the patients studied. As a consequence, the cause of allergies can be searched for among extrinsic factors that could impair 1 or several mechanisms that control the activation of basophils and possibly of other cells in some or all allergic diseases.
Our study can have therapeutic consequences. The use of probiotics capable of dampening the activation of effector cells of allergy 12 is supported by our observation that the inhibitory effect of L paracasei is fully conserved in basophils from allergic patients. Noticeably, FcR-dependent and L paracasei-induced inhibition do not compete with each other and instead have additive effects, including in allergic patients, probably because they activate different inhibitory signaling pathways. This excludes that a prophylactic administration of probiotics to nonallergic subjects 17 might antagonize physiologic FcR-dependent regulation. Allergen immunotherapy, which was conceived of as an allergen-based vaccine 1 century ago, 36 elicits a robust allergen-specific IgG response rather than a tolerance state to allergen, and in addition to (or rather than) competing with IgE antibodies for allergen, IgG antibodies are likely to form allergen-antibody complexes that coengage FcεRI and FcgRIIB on basophils. 15, 16 Passively administered IgG antibodies PBMCs from the 6 groups of subjects studied were incubated with (B, C, F, and G) or without (A, D, and E) L paracasei. They were challenged with MAR F(ab9) 2 (Fig 6, B) , MAR IgG (Fig 6, A and C) , a 93 excess of MAR F(ab9) 2 (Fig 6, D and F) , or a 183 excess of MAR F(ab9) 2 (Fig 6, E and G) . CD203c was monitored in basophils, and CD203c upregulation induced by RAHE F(ab9) 2 in cells not exposed to L paracasei (data not shown) was used as a 100% response to calculate the percentage inhibition induced by MAR IgG (Fig 6, A) , L paracasei (Fig 6, B) , MAR IgG plus L paracasei (Fig 6, C) , MAR F(ab9) 2 in excess (Fig 6, D and E) , and MAR F(ab9) 2 in excess plus L paracasei (Fig 6, F and G) .
or bispecific molecules capable of coligating, either directly 18 or indirectly, 19, 20 FcεRI with FcgRIIB have been generated, some of which have a modified Fc portion that has a markedly increased affinity for FcgRIIB. 22 Our finding that FcεRI and FcgRIIB are fully functional on basophils from allergic patients strongly supports the development of such reagents. That no intrinsic abnormality dampens regulatory mechanisms that control basophil activation in allergic patients was indeed a requirement for therapeutic approaches based on antibody-induced regulatory mechanisms to be efficient. The spectacular success of novel anticancer immunotherapeutic tools collectively referred to as immune checkpoint inhibitors 37 has been possible because regulatory mechanisms that control anticancer immunity were not impaired in patients with cancer. Therefore our study encourages development of immune checkpoint modifiers against allergic and autoimmune diseases.
Key messages
d Antibody-mediated FcεRI-and/or FcgRII-dependent positive and negative regulation, as well as lactobacilliinduced negative regulation, are fully functional in basophils from allergic patients.
d Intrinsic defects in mechanisms that control basophil activation do not account for the cause of allergic diseases.
d The finding that no intrinsic abnormality dampens mechanisms that control basophil activation in allergic patients encourages development of immune checkpoint modifiers against allergies.
